Telswit‑H Tablets provide a synergistic combination of Telmisartan 40 mg, an angiotensin II receptor blocker (ARB), and Hydrochlorothiazide 12.5 mg, a thiazide diuretic. This fixed-dose formulation is designed to effectively lower blood pressure in patients not adequately controlled by monotherapy.
Telmisartan blocks angiotensin II effects, causing vasodilation and sodium retention reduction.
Hydrochlorothiazide increases urinary sodium and water excretion, helping reduce blood volume and cardiac workload.
Enhanced antihypertensive efficacy due to complementary mechanisms
Lower risk of fluid retention, improved metabolic profile
Once-daily dosing improves adherence
Essential hypertension unresponsive to single agent therapy
Cardiovascular risk reduction in hypertensive individuals
One tablet daily, preferably in the morning. Monitor blood pressure and electrolytes periodically.
Monitor renal function and potassium levels
Use caution in patients with gout, diabetes, or electrolyte imbalance
Avoid during pregnancy and lactation
May cause dizziness, thirst, or leg cramps
Store in airtight blister packs below 25 °C, away from moisture and light.
Telswit‑H delivers a potent antihypertensive combination to optimize blood pressure control and reduce cardiovascular risk.
